[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 416,382
  • Shares Outstanding, K 338,522
  • Annual Sales, $ 4,410 K
  • Annual Income, $ -67,850 K
  • EBIT $ -66 M
  • EBITDA $ -63 M
  • 60-Month Beta 2.18
  • Price/Sales 96.65
  • Price/Cash Flow N/A
  • Price/Book 73.48

Options Overview Details

View History
  • Implied Volatility 172.33% (+7.94%)
  • Historical Volatility 65.52%
  • IV Percentile 89%
  • IV Rank 22.14%
  • IV High 544.02% on 11/14/25
  • IV Low 66.66% on 07/21/26
  • Expected Move (DTE 17) 0.2975 (23.80%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 443
  • Volume Avg (30-Day) 1,358
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 68,009
  • Open Int (30-Day) 71,353
  • Expected Range 0.9525 to 1.5475

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 3
  • High Estimate $-0.04
  • Low Estimate $-0.06
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +6.84%
on 07/29/26
1.5300 -18.30%
on 07/08/26
-0.2600 (-17.22%)
since 07/02/26
3-Month
1.1600 +7.76%
on 06/16/26
1.9000 -34.21%
on 05/04/26
-0.5500 (-30.56%)
since 05/01/26
52-Week
0.9310 +34.26%
on 08/06/25
2.7250 -54.13%
on 03/17/26
+0.2564 (+25.81%)
since 08/01/25

Most Recent Stories

More News
Ocugen to Participate in Upcoming August Investor Conferences

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.2500 (+1.63%)
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could accelerate...

OCGN : 1.2500 (+1.63%)
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.2500 (+1.63%)
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa.,...

OCGN : 1.2500 (+1.63%)
Ocugen to Participate in Upcoming July Industry Conferences

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.2500 (+1.63%)
Ocugen to Participate in Upcoming June Investor and Industry Conferences

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.2500 (+1.63%)
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing...

OCGN : 1.2500 (+1.63%)
Ocugen to Participate in Upcoming May Scientific and Investor Conferences

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.2500 (+1.63%)
Ocugen: Q1 Earnings Snapshot

Ocugen: Q1 Earnings Snapshot

OCGN : 1.2500 (+1.63%)
Ocugen Provides Business Update with First Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p

OCGN : 1.2500 (+1.63%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.3267
2nd Resistance Point 1.3033
1st Resistance Point 1.2767
Last Price 1.2500
1st Support Level 1.2267
2nd Support Level 1.2033
3rd Support Level 1.1767

See More

52-Week High 2.7250
Fibonacci 61.8% 2.0397
Fibonacci 50% 1.8280
Fibonacci 38.2% 1.6163
Last Price 1.2500
52-Week Low 0.9310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.